Skip to main content

Guilford
Old Saybrook
Deep River

Serving the Connecticut Shoreline since 1966

Guilford | Old Saybrook | Deep River
Since 1966

Menu
Home » Your Eye Health » Eye Diseases » Macular Degeneration » Treatment of Macular Degeneration

Treatment of Macular Degeneration

While there is no cure for macular degeneration, treatments do exist that can delay the progression of the disease, preserve existing vision and sometimes even improve vision loss.

Currently, there are no approved treatments to prevent or cure dry AMD, although there is evidence that indicates that certain nutritional supplements, including omega 3 fatty acids, lutein and zeaxanthin, can prevent the progression of the disease to the more advanced wet form, which can cause more severe vision loss.

There are a couple of options for treating wet AMD to slow the progression of vision loss which include medicated injections and laser therapy. These therapies are designed to stop the development of new blood vessels, to destroy existing ones and to prevent leakage into the macula – the main dangers with wet AMD.

Unfortunately, while much research continues to be conducted, currently there is no treatment and no way to fully regain vision lost by AMD. Those who have suffered significant vision loss can benefit from the many low vision devices on the market which utilize your existing vision to assist in maintaining your independence. Such devices include standing and hand-held magnifiers and telescopes and other aides that can help to improve your vision.

If you have been diagnosed with AMD, regular vision tests are essential. Close monitoring and adherence to treatment can not only prevent further vision deterioration but can sometimes even improve vision.

Effective May 17th, our Deep River location will be CLOSED on Mondays.

This will be a temporary change for the summer, and we will notify you when normal hours of operation resume.

If you need to contact this practice on a Monday, please call our Old Saybrook office at (860)-388-2020.

Our apologies for any inconvenience, and thank you for your continued support!